{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00174145,0.001374853,0.002215523,0.0003811647,0.0003289322,0.001053406,0.0006820617,0.001318574,0.001279869],"category_scores_gemma":[0.001053321,0.0005213505,0.001456232,0.000364056,0.0009343183,0.0009476592,0.0002826699,0.002228721,0.0004359407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001086279,"about_ca_system_score_gemma":0.0008355089,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007775979,"about_ca_topic_score_gemma":0.001335843,"domain_scores_codex":[0.9994055,0.0002758541,0.00002777705,0.0001023392,0.00006612322,0.0001223915],"domain_scores_gemma":[0.9993665,0.0001245612,0.0001472879,0.00007073354,0.00003771653,0.0002532592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8327516,0.0175513,0.01241836,0.000722836,0.002464383,0.0002068322,0.0002940323,0.002058537,0.03974248,0.0001818601,0.001691525,0.08991622],"study_design_scores_gemma":[0.5633526,0.3905586,0.03738273,0.00004148011,0.00138873,0.0003353622,0.0000819516,0.001650704,0.00285506,0.0002209137,0.002076892,0.00005507403],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967098,0.001944502,0.0001821981,0.0001562108,0.00004312611,0.0002460369,0.0002280612,0.00002589805,0.0004640493],"genre_scores_gemma":[0.996846,0.0008206821,0.0003249046,0.0003508392,0.0001005615,0.0003525233,0.0005297296,0.00001140688,0.0006632776],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002215523,"threshold_uncertainty_score":0.009209812,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04388713937975811,"score_gpt":0.3604510344685047,"score_spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}